Cargando…
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
AIMS: The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. METHODS AND RESULTS: Ninety-eight patients with cor...
Autores principales: | Varenhorst, Christoph, James, Stefan, Erlinge, David, Brandt, John T., Braun, Oscar Ö., Man, Michael, Siegbahn, Agneta, Walker, Joseph, Wallentin, Lars, Winters, Kenneth J., Close, Sandra L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709885/ https://www.ncbi.nlm.nih.gov/pubmed/19429918 http://dx.doi.org/10.1093/eurheartj/ehp157 |
Ejemplares similares
-
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016) -
Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017) -
Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017) -
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016) -
TRITON and Beyond: New Insights into the Profile of Prasugrel
por: Jakubowski, Joseph A, et al.
Publicado: (2012)